A pilot pharmacokinetic study of oral azacitidine (Q34786094)

4 August 2017

A pilot pharmacokinetic study of oral azacitidine (English)

1 reference

4 August 2017

1 reference

G Garcia-Manero

1

1 reference

4 August 2017

M L Stoltz

2

1 reference

4 August 2017

M R Ward

3

1 reference

4 August 2017

H Kantarjian

4

1 reference

4 August 2017

S Sharma

5

1 reference

4 August 2017

12 June 2008

1 reference

4 August 2017

1 reference

4 August 2017

22

1 reference

4 August 2017

9

1 reference

4 August 2017

1680-1684

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.145

4 August 2017

0 references

cites work

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Cancer epigenetics comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Reactivating the expression of methylation silenced genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

DNA modification, differentiation, and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

DNA methylation: past, present and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

7 January 2021

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

7 January 2021

Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

7 January 2021

5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

7 January 2021

Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.145

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.145

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference